Unlisted shares of Gaudium IVF & Women Health Ltd trade at Rs 87.5 each in the grey market, a premium of Rs 8.5 over the upper IPO price of Rs 79.
Gaudium IVF & Women Health Ltd IPO Day 2: The public offering of this fertility services provider is now on its second day of bidding. The price band for the Rs 165 crore issue has been fixed between Rs 75 and Rs 79 per share. Up to 10:15 am on the final bidding day, the IPO attracted a 1.19× subscription, with bids for 1,74,20,130 shares against the 1,46,20,340 shares on offer.
Gaudium IVF & Women Health Ltd IPO Day 2: Its retail category saw a 1.79× subscription, while the non‑institutional investors (NII) category got a 1.37× subscription.
Grey Market Premium – What It Means
According to market observers, unlisted shares of Gaudium IVF & Women Health Ltd were trading at Rs 87.5 a piece in the grey market, which is a premium of Rs 8.5 or about 10.8% over the upper IPO price of Rs 79. This premium basically tells us that investors are ready to pay more than the issue price, signalling a positive sentiment.
The grey market premium (GMP) is not fixed; it shifts with market mood. A higher GMP often points to strong demand, but it can also be speculative. So, it’s a useful barometer but not a guarantee of listing performance.
Gaudium IVF & Women Health Ltd is slated to list on both BSE and NSE with a tentative debut later this month.
Should You Subscribe? My Personal Take
Brokerage opinions are a mix of optimism and caution. JM Financial highlights that Gaudium IVF & Women Health Ltd is the first listed fertility services platform in India, boasting an industry‑leading EBITDA margin of 40.48%. That’s a sign of solid clinical standards and efficient operations. The firm’s hub‑and‑spoke model lets it bring standardised IVF services to tier‑2 and tier‑3 cities, which are still underserved.
They also point out the plan to spend Rs 50 crore on setting up 19 new centres, which could broaden the geographical footprint. The experienced clinical leadership under founder Dr Manika Khanna, who held a 99.32% pre‑IPO stake, adds credibility. The business isn’t just IVF; it also offers male infertility treatment, genetic testing, and attracts international patients from places like Canada, the UK, the US and Africa.
On the flip side, JM Financial flags several risks. Competition is intense, with established fertility chains eyeing the same markets. New centres need regulatory clearances, which can delay expansion. There’s also the promoter’s offer‑for‑sale of 0.95 crore shares – that’s a partial stake dilution which could worry some investors.
Another concern is talent retention. Specialist doctors are in high demand, and attracting them to newer, smaller centres can be challenging. Patient acquisition costs are rising, especially in saturated metro areas.
BP Wealth adds that at the upper price band, the IPO is valued at a price‑to‑earnings multiple of 25.3× for FY25 earnings. They give a “Subscribe” rating, noting that Gaudium IVF & Women Health Ltd’s growth plan leans on calibrated expansion, stronger hub operations, better utilisation of centres, and brand building in high‑growth urban and semi‑urban markets.
From a personal viewpoint, I see the promise in the model – a central hub with satellite clinics can bring consistency in treatment quality across distant cities. My aunt, who lives in a tier‑2 town, once told me she had to travel to a metro city for IVF; a local centre could have saved a lot of hassle. That’s exactly the gap Gaudium IVF & Women Health Ltd is trying to fill.
However, the risks are real. If the company expands too fast without securing the right doctors or regulatory approvals, the promised efficiency could erode. Also, the promoter’s reduction of stake may signal a shift in confidence, even if it’s just a liquidity move.
Overall, if you’re comfortable with a growth‑oriented play in a niche but expanding sector, the IPO looks attractive. If you prefer defensive, low‑risk stocks, you might sit this one out.
More Details on the Offering
Gaudium IVF & Women Health Ltd announced that it has raised Rs 49.5 crore from anchor investors. The Rs 165 crore IPO will conclude soon, making Gaudium IVF & Women Health Ltd the first company in the fertility care space to go public.
The proposed issue includes a fresh issue of 1.14 crore equity shares and an offer‑for‑sale of nearly 95 lakh shares by promoter Dr Manika Khanna.
Proceeds from the fresh issue are earmarked for setting up 19 new IVF centres across India, paying down existing debt, and general corporate purposes.
Founded by Dr Manika Khanna, Gaudium IVF & Women Health Ltd has become a pioneer in assisted reproductive technologies in India. It runs a hub‑and‑spoke network with seven hubs and 28 spokes spread across multiple states, enabling it to reach a wide patient base.
Financially, the company reported revenue from operations of Rs 70.72 crore and a profit after tax of Rs 19.13 crore for the financial year ending FY25. In the previous fiscal year, revenue was Rs 47.89 crore, with a PAT of Rs 10.31 crore.
Indira IVF Hospital Ltd has also filed draft papers with SEBI to raise funds through an IPO, indicating a growing interest in the fertility sector.
According to an Infomerics Research report, the broader Indian IVF market is projected to grow at a CAGR of 13 % over the next decade, expanding from $1.32 billion today to $4.54 billion within ten years. This offers a sizable growth runway for players like Gaudium IVF & Women Health Ltd.
Practical Observations from the Ground
When I visited a Gaudium IVF hub in Pune last year, the facilities felt more like a modern hospital than a boutique clinic. The staff were well‑trained, and the process seemed streamlined – exactly what a hub‑and‑spoke model promises.
My neighbour in a smaller town complained that the nearest IVF centre was over an hour’s drive away, and she had to stay in a metro city for treatment. If a spoke opens nearby, it could cut down travel time and expenses for many families.
On the other hand, I heard a junior doctor mention that the turnover in specialised reproductive medicine is high. Retaining talent in newer centres might need attractive packages, which could affect margins.
These real‑world snippets make the numbers in the prospectus feel a bit more tangible.
Final Thoughts – To Subscribe or Not?
Summing it up, Gaudium IVF & Women Health Ltd’s IPO has a decent subscription level, a healthy grey market premium, and a business model that tackles a genuine need in tier‑2 and tier‑3 cities. The financials show strong profit growth and impressive margins, which is encouraging.
Yet, the path ahead is not without hurdles – competitive pressure, regulatory clearances, talent acquisition and the promoter’s stake dilution are all factors that could weigh on performance.
If you believe in the long‑term growth of the IVF market in India and are comfortable with a company that is still in an expansion phase, the IPO could be a good addition to your portfolio. If you prefer a more stable, less risky investment, you might want to wait until the company establishes a proven track record post‑listing.
In my personal view, the story feels promising enough to consider a modest subscription, especially given the attractive grey market premium. But remember, every investment carries risk, so do your own research and perhaps talk to a financial adviser before making a decision.
